EntreMed (ENMD) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
EntreMed (ENMD)

An SI Board Since January 1997

Posts	SubjectMarks	Bans	Symbol
2135	59	0	ENMD

Emcee: Mark Wise	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
235	There are three versions of endostatin. The one in the report was murine. It	David Winkler	-	12/3/1997
234	David, >>I will be amazed if human trials are not initiated sooner than	Michael Greene	-	12/3/1997
233	Not only production is easy, so is administration. Maybe as easy as a patch li	David Winkler	-	12/3/1997
232	David: Do I understand correctly from this that the production of recombinant	John Bloxom	-	12/3/1997
231	John, sorry for delayed response, but I was feeling guilty about not doing enou	David Winkler	-	12/2/1997
230	I did mention a horizon of 3-4 quarters atleast... so before we see any mention	Graham Dellaire	-	12/2/1997
229	Well, I can't tell you for support strickly. We are waiting for that doubl	Graham Dellaire	-	12/2/1997
228	<<This is not likely since the protein is active right out of bacteria wi	John Bloxom	-	12/2/1997
227	Since these compounds don't do anything to the tumors themselves I am not s	David Winkler	-	12/2/1997
226	Thanks, David. I would think that before they could go into the clinic, they wo	Andrew H	-	12/2/1997
225	The quote should have been attributed to Dr. Klausner, directer of NCI. He mad	David Winkler	-	12/2/1997
224	>>NIH director Varmus has said that this work will be put on the fast tra	Andrew H	-	12/2/1997
223	NIH director Varmus has said that this work will be put on the fast track. I w	David Winkler	-	12/2/1997
222	>>Does anyone know if endostatin will be distributed by a big pharma... i	Andrew H	-	12/2/1997
221	On the price issue, bear in mind that November is the lowest month for net cash	John Bloxom	-	12/2/1997
220	Has anyone seen the Nature letter yet? We are on about a 6 day delay after pub	David Winkler	-	12/2/1997
219	Any idea what the support levels are? We are hitting the 12 area and if suppo	Double Dipper	-	12/2/1997
218	Kevin, there could be another 3-4 quraters of red atleast. It takes a lot of s	Graham Dellaire	-	12/2/1997
217	David, Could you advise what are some of the other profitable aspects of this	Double Dipper	-	12/2/1997
216	Hold on as long as you can. The science is rock solid, IMHO. The timing may b	David Winkler	-	12/2/1997
215	What a novel idea to go to the original work instead of speculating. I am look	David Winkler	-	12/2/1997
214	David, I looked up the Cell article from Jan. Endostatin studies were done in	Graham Dellaire	-	12/2/1997
213	>SEPR traded at 15 and less virtually every day from July 96 through October	Haolin Ni	-	12/1/1997
212	<<How can you buy it at $14 in last fall when news released.>> SEP	John Bloxom	-	12/1/1997
211	Tom, To put it mildly, I am angry over the shenangins the MM's were pulling	Arthur Radley	-	12/1/1997

Go to reply# or date (mm/dd/yy):